Glaukos enters exclusive license agreement with RevOpsis Therapeutics for RO-104

Glaukos announced an exclusive license agreement with RevOpsis Therapeutics to develop and commercialize RO-104, a novel tri-specific biologic.

Detected & updated continuously · Source: Nebula